Bimzelx

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

Approximately 125 million people worldwide are affected by some form of psoriasis

The inflammatory skin disease affects approximately one in every 100 people in the US

The inflammatory skin disease affects about 1% of the population in most studied countries

The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy

Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

The inflammatory skin disease affects an estimated 1% of the population in most studied countries

Affecting 90% of psoriasis patients, the chronic autoimmune disease causes red, itchy, scaly patches

The drug was associated with sustained improvements in the signs and symptoms of the inflammatory skin disease

The skin disease affects an estimated 1% of the population in most studied countries

More than 7.5 million adults in the US are affected by some form of the chronic inflammatory condition